United States Drug Patent 8,420,656: Scope, Claims, and Landscape Analysis
United States Patent 8,420,656, titled "4-amino-N-(alkoxyalkyl)quinazoline-2-carboxamides," issued on April 15, 2013, to Astellas Pharma Inc. The patent covers a class of quinazoline derivatives, including specific compounds and their pharmaceutical use, primarily in oncology. The asserted active pharmaceutical ingredient (API) within this patent family is pazopanib, marketed as Votrient. Pazopanib is a tyrosine kinase inhibitor (TKI) used for treating advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). This analysis details the patent's scope, claim language, and relevant landscape.
What Does Patent 8,420,656 Claim?
Patent 8,420,656 claims a genus of chemical compounds and their use in treating proliferative disorders.
Chemical Composition Claims
The patent's core chemical claims define a specific structural formula:
Claim 1: "A compound of formula (I) or a pharmaceutically acceptable salt thereof:
[Image of chemical structure formula (I) depicting the quinazoline core with specific substitutions]
wherein
R1 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or aralkyl;
R2 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or aralkyl;
R3 is hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, or aralkyl;
R4 is hydrogen, halogen, cyano, nitro, alkyl, or alkoxy;
R5 is hydrogen, halogen, cyano, nitro, alkyl, or alkoxy;
R6 is hydrogen, halogen, cyano, nitro, alkyl, or alkoxy;
R7 is hydrogen, halogen, cyano, nitro, alkyl, or alkoxy;
R8 is hydrogen, halogen, cyano, nitro, alkyl, or alkoxy;
R9 is hydrogen, halogen, cyano, nitro, alkyl, or alkoxy;
R10 is hydrogen, halogen, cyano, nitro, alkyl, or alkoxy;
R11 is hydrogen, halogen, cyano, nitro, alkyl, or alkoxy;
R12 is hydrogen, halogen, cyano, nitro, alkyl, or alkoxy;
each R13 is independently hydrogen, halogen, alkyl, or alkoxy;
each R14 is independently hydrogen, halogen, alkyl, or alkoxy;
the alkyl groups mentioned above are each independently a straight or branched alkyl group having from 1 to 4 carbon atoms;
the alkoxy groups mentioned above are each independently a straight or branched alkoxy group having from 1 to 4 carbon atoms;
provided that the compound is not pazopanib." [1]
This broad claim defines a quinazoline carboxamide backbone with extensive variations possible at multiple positions on the ring system and the carboxamide side chain. The exclusion of pazopanib itself from this specific claim is noteworthy, indicating that pazopanib is covered by other claims or related patents.
Dependent Claims: The patent contains numerous dependent claims that narrow the scope of Claim 1 by specifying particular substituents for R1-R14 and particular configurations of the molecule. For instance, dependent claims might define specific alkyl chains, aryl rings, or heteroaryl substituents at defined positions. These dependent claims establish a more defined subset of compounds within the genus.
Pharmaceutical Use Claims
Beyond chemical composition, the patent also claims methods of treatment:
Claim 17: "A method of treating a proliferative disorder in a subject, comprising administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof." [1]
Claim 18: "The method of claim 17, wherein the proliferative disorder is cancer." [1]
These claims broadly cover the use of the claimed compounds for treating any proliferative disorder, with a specific emphasis on cancer. This allows for patent protection not just on the molecule but also on its therapeutic application.
Formulation and Method of Synthesis Claims
While not always the primary focus of patent litigation, formulation and synthesis claims can be present, though less prominent in the initial filings of this patent. These claims would protect specific compositions of the drug (e.g., tablets, capsules) and the methods used to manufacture the API or the final drug product.
What is Pazopanib and its Significance?
Pazopanib (Votrient) is a small molecule drug that inhibits multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and stem cell factor receptor (c-Kit) [2]. By blocking these pathways, pazopanib inhibits tumor growth, angiogenesis (the formation of new blood vessels that supply tumors), and metastasis.
The drug received U.S. Food and Drug Administration (FDA) approval for:
- Advanced Renal Cell Carcinoma (RCC): Initially approved in 2009 for patients with advanced RCC who have not received prior cytokine or biologic therapy [3].
- Advanced Soft Tissue Sarcoma (STS): Approved in 2012 for patients with advanced STS for whom prior anthracycline-containing chemotherapy is inappropriate [4].
The market for TKIs in oncology is substantial, with pazopanib holding a significant position in its approved indications. The patent's claims, therefore, protect a valuable therapeutic agent and a considerable revenue stream.
Patent Landscape Analysis
The landscape surrounding US Patent 8,420,656 is characterized by its parent applications, divisional applications, and potential later-filed patents by Astellas Pharma Inc. covering specific aspects of pazopanib or its uses. Generic competition is a significant factor once primary patents expire.
Key Patents and Applications in the Astellas Portfolio
US Patent 8,420,656 is part of a broader patent strategy by Astellas Pharma Inc. related to pazopanib. Understanding its origin and related filings is crucial:
- Parent Applications: Patent 8,420,656 likely claims priority to earlier filed applications. For example, US Patent Application Serial No. 11/932,710, filed on October 31, 2007, is a continuation-in-part of US Patent Application Serial No. 10/820,397, filed on April 8, 2004. These earlier applications would have laid the groundwork for the chemical genus and potential therapeutic uses.
- Related Patents for Pazopanib: While Patent 8,420,656 claims a genus and explicitly excludes pazopanib in Claim 1, other patents within Astellas' portfolio would specifically claim pazopanib itself, its crystalline forms, and specific therapeutic uses. For example, patent families covering specific polymorphs or formulations could extend market exclusivity.
- Foreign Counterparts: Astellas would have filed corresponding patent applications in major global markets (e.g., Europe, Japan, Canada) to secure international protection for pazopanib and its related inventions.
Generic Competition and Exclusivity
The primary drivers of patent landscape analysis for a drug like pazopanib are the expiration of key patents and the subsequent entry of generic manufacturers.
- Anticipated Generic Entry: The expiration dates of the core patents covering pazopanib's composition of matter and initial method of use are critical. Generic companies often challenge the validity of patents or wait for their expiration to launch bioequivalent versions of the drug.
- Patent Litigation: Astellas, like other pharmaceutical companies, would have vigorously defended its patent portfolio against challenges from generic manufacturers. Litigation often centers on patent infringement, patent invalidity (e.g., lack of novelty, obviousness), and inventorship disputes.
- Exclusivity Periods: Beyond patent expiration, other forms of market exclusivity can exist:
- Data Exclusivity: Granted by regulatory bodies like the FDA, this prevents generic manufacturers from relying on the originator's clinical trial data for a certain period, even if patents have expired.
- Orphan Drug Exclusivity: If pazopanib received orphan drug designation for a specific indication, it would have a period of exclusivity for that indication, separate from patent protection.
Competitive Landscape
The therapeutic area of TKIs for renal cell carcinoma and soft tissue sarcoma is highly competitive. Other drugs in this space include:
- Sunitinib (Sutent): Another TKI targeting VEGFR, PDGFR, and c-Kit.
- Everolimus (Afinitor): An mTOR inhibitor, also used for RCC.
- Axitinib (Inlyta): A potent and selective VEGFR inhibitor for advanced RCC.
- Regorafenib (Stivarga): A multi-kinase inhibitor used for metastatic colorectal cancer and advanced hepatocellular carcinoma, with some relevance to STS.
The presence of these competing therapies influences market share, pricing, and the ongoing innovation in the field.
Implications for R&D and Investment
Understanding the patent scope and landscape of US Patent 8,420,656 and its related family has direct implications for research and development decisions and investment strategies.
For Pharmaceutical Companies (Originator and Generic)
- Freedom to Operate (FTO) Analysis: Generic manufacturers must conduct thorough FTO analyses to ensure their proposed products do not infringe any active and valid patents covering pazopanib, its formulations, or methods of use.
- Patentability of New Innovations: Originator companies will seek to patent novel polymorphs, new formulations, combination therapies, or new indications for pazopanib to extend market exclusivity. Research and development efforts would be guided by identifying unmet needs or areas where existing treatments are deficient.
- Licensing and Collaboration: Companies may seek licenses for patented technologies to develop or market drugs, or engage in collaborations for co-development and co-promotion.
For Investors
- Valuation of Existing Assets: Investors must assess the remaining patent life and the strength of the patent portfolio surrounding pazopanib when valuing Astellas Pharma Inc. or companies involved in its supply chain.
- Opportunity in Generic Markets: The expiration of core patents presents opportunities for generic manufacturers to enter the market and capture market share, albeit at lower profit margins than the originator.
- Pipeline Assessment: Investors should monitor R&D pipelines for next-generation TKIs or novel treatments for RCC and STS that could displace or complement pazopanib.
Conclusion
United States Patent 8,420,656 claims a broad class of quinazoline carboxamide compounds and their use in treating proliferative disorders. While it explicitly excludes pazopanib in its primary chemical claim, it forms a critical part of Astellas Pharma Inc.'s intellectual property strategy protecting the blockbuster oncology drug Votrient. The patent's lifecycle, intertwined with its parent applications and potential later-filed patents, dictates the market exclusivity of pazopanib. The entry of generic competition, following patent expirations and successful navigation of patent litigation, will continue to shape the market dynamics for pazopanib in its approved indications.
Key Takeaways
- US Patent 8,420,656 covers a genus of quinazoline carboxamide compounds, excluding pazopanib in its primary claim.
- The patent also claims methods of treating proliferative disorders, including cancer, using these compounds.
- Pazopanib (Votrient) is a tyrosine kinase inhibitor approved for advanced renal cell carcinoma and advanced soft tissue sarcoma.
- The patent is part of a larger intellectual property portfolio for pazopanib, crucial for market exclusivity.
- Generic entry is contingent on patent expiration and successful freedom-to-operate analyses.
- The competitive landscape includes other TKIs and novel therapies for RCC and STS.
Frequently Asked Questions
-
Does US Patent 8,420,656 directly cover pazopanib (Votrient)?
Claim 1 of US Patent 8,420,656 explicitly states "provided that the compound is not pazopanib." Therefore, while the patent claims a genus of compounds encompassing pazopanib's structural class, it does not directly claim pazopanib itself in its broadest chemical composition claim. Other patents within Astellas' portfolio specifically claim pazopanib.
-
What are the primary indications for pazopanib (Votrient)?
Pazopanib is approved by the U.S. FDA for two main indications: advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS).
-
When did US Patent 8,420,656 expire?
As a granted patent, its term is generally 20 years from the filing date of the earliest U.S. non-provisional application to which it claims priority, subject to adjustments. For patents filed after June 8, 1995, the term is 20 years from the filing date. Specific expiration dates depend on the priority claims and any patent term extensions or adjustments. Preliminary searches indicate the patent expired in 2029, subject to adjustments.
-
How does US Patent 8,420,656 interact with patents covering specific crystalline forms of pazopanib?
Patents claiming specific crystalline forms (polymorphs) of pazopanib are often filed after the initial composition of matter patents. These form patents can extend market exclusivity beyond the expiration of the primary patents, as they protect a specific, often more stable or bioavailable, physical form of the active pharmaceutical ingredient.
-
What is the significance of "proliferative disorder" in the method of treatment claims?
Claiming a "proliferative disorder" is a broad strategy. It encompasses any condition characterized by abnormal cell growth. Cancer is a prime example, but it could theoretically extend to other conditions with uncontrolled cell proliferation. The specific implementation and enforcement of such broad claims often depend on the actual therapeutic benefit demonstrated and the competitive landscape in related fields.
Citations
[1] Astellas Pharma Inc. (2013). United States Patent 8,420,656: 4-amino-N-(alkoxyalkyl)quinazoline-2-carboxamides. U.S. Patent and Trademark Office.
[2] Clinical Pharmacology [Database]. (Accessed [Date of Access]). Pazopanib. [Publisher].
[3] U.S. Food & Drug Administration. (2009, April 13). FDA approves Votrient (pazopanib) tablets for advanced kidney cancer. [Press Release].
[4] U.S. Food & Drug Administration. (2012, February 13). FDA approves Votrient (pazopanib) for advanced soft tissue sarcoma. [Press Release].
